Selexipag

(Uptravi)

Selexipag

Drug updated on 11/10/2023

Dosage FormTablet (oral; 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1000 mcg, 1200 mcg, 1400 mcg, 1600 mcg); Injection (Intravenous; 1800 mcg)
Drug ClassProstacyclin receptor agonists
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.